Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35285 Vaxart, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | | 59-1212264 | | - ...

Start Time: 16:30 January 1, 0000 5:01 PM ET Vaxart, Inc. (NASDAQ:VXRT) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Sean Tucker - SVP and Chief Scientific Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings, and welcome to the Vaxart Business Update and Second Quart ...

Table of Contents Commission file number: 001-35285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to If an emerging growth company, indicate by check mark if the registrant has elected not to use the exten ...

Vaxart, Inc. (NASDAQ:VXRT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Mayank Mamtani - B. Riley Securities Roger Song - Jefferies Operator Greetings and welcome to Vaxart Business Update and First Quarter 2023 Financial Results C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35285 Vaxart, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | | 59-1212264 | | --- | ...

Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Brant Biehn - Senior Vice President, Business Operations Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings. Welcome to Vaxart Business Update and Full Year 2022 Financial ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35285 Vaxart, Inc. | (Exact Name of Registrant as Specified in its Charter) | | | | --- | --- | --- | | Delaware | ...

Vaxart, Inc. (NASDAQ:VXRT) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Sahil Kazmi - B. Riley Securities FBR Operator Greetings, and welcome to the Vaxart's Third Quarter 2022 Business Update and Financial Results Conference Call. A question- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35285 Vaxart, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | | 59-1212264 | | - ...

Financial Data and Key Metrics Changes - The company reported a strong financial position with $131 million in cash and cash equivalents as of June 30, 2022, providing a runway until the second half of 2023 [29]. Business Line Data and Key Metrics Changes - The company is progressing with two key clinical programs: COVID-19 and norovirus vaccines, with ongoing trials and encouraging preliminary data [11][19]. - The COVID-19 vaccine program aims to leverage mucosal immunity for broader protection against variants, with plans for both monovalent and bivalent constructs [9][10]. Market Data and Key Metrics Changes - The COVID-19 pandemic has highlighted the need for next-generation vaccines, particularly oral vaccines that can be administered easily and quickly [7][8]. - The norovirus vaccine program shows promise, especially in older adults, with data suggesting robust immune responses similar to younger populations [11][25]. Company Strategy and Development Direction - The company aims to revolutionize vaccination through oral tablet vaccines, which could simplify mass vaccination campaigns and improve accessibility [6][14]. - Vaxart is committed to advancing multiple programs in parallel, focusing on the development of oral vaccines that can address public health challenges [7][18]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position, stating it is the best it has been in its 15-year history, with significant internal capabilities developed over the past two years [7]. - The management highlighted the importance of mucosal immunity and the potential of oral vaccines to address the shortcomings of current injected vaccines [12][15]. Other Important Information - The company is preparing for several important milestones, including top-line data from the Phase II COVID-19 clinical study expected in Q3 2022 and the initiation of a Phase II trial for the bivalent norovirus vaccine in Q4 2022 [29][30]. - The company is also working with the Indian government to initiate a Phase Ib trial for its COVID-19 vaccine [24]. Q&A Session Summary Question: What do you think the regulatory authorities would require for a vaccine approved as a booster for COVID? - Management indicated that ongoing dialogue with regulatory authorities is crucial, and data from the challenge study will be important for establishing a pathway forward [34]. Question: Can you speculate on the size and duration of the Phase II trial for the bivalent norovirus vaccine? - The upcoming Phase II trial will focus on both immunogenicity and preliminary efficacy, leveraging data from the challenge study to inform future studies [36]. Question: Where do you see the norovirus vaccine fitting into the vaccination schedule in the U.S.? - The norovirus vaccine is expected to benefit both younger children and older adults, with significant annual costs associated with norovirus infections in the U.S. [38]. Question: What are your thoughts on the ability of the Wuhan S-only vaccine to provide protection against BA.4 and BA.5? - Management acknowledged that while previous infections may provide some protection, they are focused on evaluating cross-reactivity and the potential for improved protection with new constructs [40][43]. Question: How quickly can you ramp up manufacturing of the new constructs? - The company has internal manufacturing capabilities that allow for quick ramp-up of production for new vaccine constructs [44]. Question: What is your approach to potential partnerships for the COVID-19 or norovirus programs? - The company is open to discussions about partnerships to maximize shareholder value and accelerate program development [59].